This pipeline maps genes, with mutation or copy number alteration AND this alteration is highly correlated with mRNA expression, to pathways curated in the KEGG and BIOCARTA databases. It identifies pathways significantly enriched with these genes. The pipeline also identifies pathways significantly enriched with marker genes of each expression subtype of cancer.
genes with mutation: identified by the Mutation_Significance pipeline
genes with copy number alteration: identified by the CopyNumber_Gistic2 pipeline
correlation between copy number and mRNA expression: identified by the Correlate_CopyNumber_vs_mRNA pipeline
marker genes and expression subtypes: identified by the mRNAConsensusClustering pipeline
There are 210 genes with significant mutation (Q value <= 0.1) and 386 genes with significant copy number alteration (Q value <= 0.25). The identified marker genes (Q value <= 0.01 or within top 2000) are 1241 for subtype 1, 1241 for subtype 2, 1241 for subtype 3. Pathways significantly enriched with these genes (Q value <= 0.01) are identified :
8 pathways significantly enriched with genes with copy number alteration or mutation.
11 pathways significantly enriched with marker genes of gene expression subtype 1
0 pathways significantly enriched with marker genes of gene expression subtype 2
4 pathways significantly enriched with marker genes of gene expression subtype 3
Pathway | Nof Genes | Nof CNV_Mut | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_ETS_PATHWAY | 18 | 6 | 3.6 | 0 | 0.0021 |
KEGG_ENDOMETRIAL_CANCER | 52 | 9 | 2.6 | 0 | 0.0021 |
BIOCARTA_HIVNEF_PATHWAY | 56 | 8 | 2.3 | 0.0002 | 0.0067 |
BIOCARTA_RACCYCD_PATHWAY | 26 | 6 | 3 | 0.0001 | 0.0067 |
BIOCARTA_TNFR1_PATHWAY | 29 | 6 | 2.9 | 0.0001 | 0.0067 |
E2F1,HRAS,E2F4,RBL2,SIN3A,ETV3
HRAS,CASP9,ILK,CCND1,ERBB2,CDH1,APC,RAF1,NRAS
BAG4,CASP9,CASP8,CASP2,TRAF2,MAP3K1,RASA1,TRADD
E2F1,HRAS,CCNE1,RAC1,RAF1,CCND1
TRAF2,BAG4,MAP3K1,CASP8,CASP2,TRADD
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_CELL_CYCLE | 128 | 30 | 2.2 | 0 | 0 |
KEGG_OOCYTE_MEIOSIS | 114 | 19 | 1.6 | 0 | 0.0007 |
KEGG_PATHWAYS_IN_CANCER | 328 | 38 | 1.1 | 0 | 0.0007 |
BIOCARTA_CELLCYCLE_PATHWAY | 23 | 8 | 2.7 | 0 | 0.0012 |
KEGG_DNA_REPLICATION | 36 | 9 | 2.2 | 0.0001 | 0.0052 |
DBF4,TTK,PTTG2,PTTG1,CCNA1,CCNA2,RBL1,ANAPC4,SKP2,ORC1L,CHEK1,ANAPC11,CDC20,PLK1,E2F1,CCNE1,CDC45L,CDC7,CDC2,CCNH,MCM2,MCM4,CDK2,MCM6,BUB1B,GADD45A,BUB1,CDC25C,CCNB1,CCNB2
PTTG2,PTTG1,PGR,SGOL1,ANAPC4,ANAPC11,FBXO5,CDC20,PLK1,CCNE1,CDC2,AKR1B1,CDK2,CALML3,BUB1,CDC25C,CCNB1,RPS6KA6,CCNB2
HRAS,CCNA1,SKP2,CTNNA2,VEGFB,LAMC2,LAMB1,FH,BMP4,BMP2,TCF7,FGF8,CCNE1,FGF3,AKR1B1,CTBP2,RAD51,BIRC5,FZD3,NRAS,PTCH1,TCEB1,FGF19,STK36,FGF12,MMP2,WNT6,RET,FGF20,WNT5A,FGFR3,GRB2,AXIN2,E2F1,LEF1,CDK2,EGLN1,FZD10
E2F1,CDC2,CCNH,RBL1,CDK2,CCNB1,CCNE1,CCNA1
POLA2,FEN1,MCM2,RNASEH2A,MCM4,MCM6,RFC3,RFC4,RFC2
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
WNT_SIGNALING | 89 | 6 | 2.9 | 0.0001 | 0.046 |
KEGG_BASAL_CELL_CARCINOMA | 55 | 4 | 3 | 0.0014 | 0.23 |
BIOCARTA_NO2IL12_PATHWAY | 17 | 2 | 3.7 | 0.0097 | 0.4 |
BIOCARTA_TOB1_PATHWAY | 21 | 2 | 3.6 | 0.012 | 0.4 |
BIOCARTA_CTLA4_PATHWAY | 21 | 2 | 3.6 | 0.011 | 0.4 |
WNT4,WNT6,WNT11,ACTB,FZD7,KREMEN1
WNT4,WNT6,WNT11,FZD7
CD3D,CXCR3
CD3D,TOB1
CD3D,CTLA4
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_CELL_CYCLE | 128 | 19 | 1.9 | 0 | 0.0003 |
KEGG_CELL_ADHESION_MOLECULES_CAMS | 134 | 17 | 1.6 | 0 | 0.0043 |
KEGG_TYPE_I_DIABETES_MELLITUS | 44 | 9 | 2.4 | 0 | 0.0043 |
KEGG_GRAFT_VERSUS_HOST_DISEASE | 42 | 8 | 2.4 | 0.0001 | 0.0098 |
KEGG_OOCYTE_MEIOSIS | 114 | 14 | 1.6 | 0.0002 | 0.016 |
PTTG2,PTTG1,CDKN2A,ANAPC4,ESPL1,CDC20,CDKN1C,E2F1,CCNE1,MCM2,RB1,MCM4,MDM2,BUB1B,GADD45B,BUB1,CDC25C,CDC25A,CDC25B
L1CAM,HLA-DPA1,HLA-DRA,ITGAL,ITGB2,HLA-DRB5,HLA-DPB1,CLDN6,HLA-DMB,HLA-DMA,PDCD1,SDC1,CD2,SELPLG,PTPRC,NLGN1,NLGN2
FASLG,HLA-DMB,HLA-DMA,HLA-DRB5,HLA-DPB1,GAD1,ICA1,HLA-DPA1,HLA-DRA
FASLG,HLA-DMB,HLA-DMA,HLA-DRB5,HLA-DPB1,HLA-DPA1,KLRC1,HLA-DRA
PTTG2,AURKA,PTTG1,PGR,ANAPC4,ESPL1,CDC20,CCNE1,CALML3,BUB1,CALML6,CDC25C,RPS6KA6,ADCY9
Let genes with copy number alteration or mutation be query genes. Let marker genes of specific identified subtypes be query genes. The Enrichment is calculated as:
-
Enrichment = log2 (# of query genes in the pathway/# No of query genes) - log2 (# of genes in the pathway/# of human genes)
The statistical signficance of the pathways that are enriched with genes with copy number alteration or mutation, and the pathways that are enriched with markers genes of specific identified subtypes is measured by P value.
-
P value = Fisher exact P value
The Q value is for adjusting P value for multiple testing. A public available R package is used to calculate the Q value.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.